
OrthoPediatrics (KIDS) Stock Forecast & Price Target
OrthoPediatrics (KIDS) Analyst Ratings
Bulls say
OrthoPediatrics Corp is demonstrating a robust performance, with Trauma & Deformity sales increasing by 17.3% to $44.1 million, surpassing expectations, while EBITDA margins improved significantly by 280 basis points year-over-year, highlighting effective cost management and operational efficiency. The company's consistent growth in core dynamics, particularly with over 20% growth in OPSB sales, positions it favorably for future expansion. Furthermore, the introduction of new products is anticipated to enhance margins and drive further revenue growth, presenting a strong financial outlook for the company.
Bears say
OrthoPediatrics Corp is facing several fundamental challenges that contribute to a negative outlook on its stock, including a slowdown in revenue growth, which decelerated to 12.2% in the third quarter of 2025 from 15.7% in the previous quarter. The company has also observed a decrease in the deployment of surgical sets, down to $16.0 million from $17.2 million, indicating potential issues in sales rep retention and the efficacy of new product launches. Additionally, OrthoPediatrics has revised downward its fiscal year 2025 revenue guidance amid these challenges, signaling further erosion in its financial performance.
This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares